MedTrace Logo

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

NCT00116467 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2007-12-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

Conditions

  • Acute Myelogenous Leukemia

Interventions

BIOLOGICAL

GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)

Sponsors & Collaborators

  • Cell Genesys

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116467 on ClinicalTrials.gov